Literature DB >> 27322438

Clinical trials of CD19-targeted CAR-modified T cell therapy; a complex and varied landscape.

Cameron J Turtle1,2, David G Maloney1,2.   

Abstract

Entities:  

Keywords:  Chimeric antigen receptor; T cells; acute lymphoblastic leukemia; cellular therapy; chronic lymphocytic leukemia; immunotherapy; non-Hodgkin lymphoma

Mesh：

Substances：

Year:  2016        PMID： 27322438     DOI： 10.1080/17474086.2016.1203251

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN： 1747-4094            Impact factor:   2.929


× No keyword cloud information.
  10 in total

Review 1.  Potential applications of nanoparticles in cancer immunotherapy.

Authors:  Yimei Jia; Abdelwahab Omri; Lakshmi Krishnan; Michael J McCluskie
Journal:  Hum Vaccin Immunother       Date:  2016-11-21       Impact factor: 3.452

Review 2.  Monitoring of the Immune Dysfunction in Cancer Patients.

Authors:  Saskia J A M Santegoets; Marij J P Welters; Sjoerd H van der Burg
Journal:  Vaccines (Basel)       Date:  2016-09-02

3.  Evaluating in vivo efficacy - toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells.

Authors:  Inez Johanna; Trudy Straetemans; Sabine Heijhuurs; Tineke Aarts-Riemens; Håkan Norell; Laura Bongiovanni; Alain de Bruin; Zsolt Sebestyen; Jürgen Kuball
Journal:  J Immunother Cancer       Date:  2019-03-12       Impact factor: 13.751

Review 4.  Proceedings From the First International Workshop at Sidra Medicine: "Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development", 15th-16th February 2019, Doha, Qatar.

Authors:  Bella Guerrouahen; Muhammad Elnaggar; Anjud Al-Mohannadi; Dhanya Kizhakayil; Chiara Bonini; Reuben Benjamin; Renier Brentjens; Christian J Buchholz; Giulia Casorati; Soldano Ferrone; Frederick L Locke; Francisco Martin; Axel Schambach; Cameron Turtle; Paul Veys; Hans J van der Vliet; Cristina Maccalli
Journal:  Front Immunol       Date:  2021-01-14       Impact factor: 7.561

Review 5.  When Onco-Immunotherapy Meets Cold Atmospheric Plasma: Implications on CAR-T Therapies.

Authors:  Xiaofeng Dai; Jitian Li; Yiming Chen; Kostya Ken Ostrikov
Journal:  Front Oncol       Date:  2022-02-23       Impact factor: 6.244

6.  Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse.

Authors:  Robson G Dossa; Tanya Cunningham; Daniel Sommermeyer; Indira Medina-Rodriguez; Melinda A Biernacki; Kimberly Foster; Marie Bleakley
Journal:  Blood       Date:  2017-10-19       Impact factor: 25.476

Review 7.  Defining success with cellular therapeutics: the current landscape for clinical end point and toxicity analysis.

Authors:  Leslie S Kean
Journal:  Blood       Date:  2018-05-04       Impact factor: 25.476

8.  CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies.

Authors:  Li-Na Zhang; Yongping Song; Delong Liu
Journal:  J Hematol Oncol       Date:  2018-03-15       Impact factor: 17.388

9.  Clinical trials of CAR-T cells in China.

Authors:  Bingshan Liu; Yongping Song; Delong Liu
Journal:  J Hematol Oncol       Date:  2017-10-23       Impact factor: 17.388

10.  Robust CAR-T memory formation and function via hematopoietic stem cell delivery.

Authors:  Anjie Zhen; Mayra A Carrillo; Wenli Mu; Valerie Rezek; Heather Martin; Philip Hamid; Irvin S Y Chen; Otto O Yang; Jerome A Zack; Scott G Kitchen
Journal:  PLoS Pathog       Date:  2021-04-01       Impact factor: 6.823
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.